Merrimack: Credit Suisse Antibody Day 2015 (Merrimack) - May 8, 2015 - “Safety: Safety is consistent with expected EGFR and irinotecan toxicities”; “Efficacy: Prolonged responses up to 87 weeks, Stable disease > 4 months in 9/27 CRC patients, Partial responses in 7 patients (5/7 are CRC)”
P1 data • Colorectal Cancer • Oncology
|